These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39370961)

  • 1. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
    Reshef A; Hsu C; Katelaris CH; Li PH; Magerl M; Yamagami K; Guilarte M; Keith PK; Bernstein JA; Lawo JP; Shetty H; Pollen M; Wieman L; Craig TJ;
    Allergy; 2024 Oct; ():. PubMed ID: 39370961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
    Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
    Craig TJ; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Alexandru Bica M; Jacobs I; Pragst I; Magerl M
    Lancet Haematol; 2024 Jun; 11(6):e436-e447. PubMed ID: 38710185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
    Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
    Petersen RS; Bordone L; Riedl MA; Tachdjian R; Craig TJ; Lumry WR; Manning ME; Bernstein JA; Raasch J; Zuraw BL; Deng Y; Newman KB; Alexander VJ; Lui C; Schneider E; Cohn DM
    Allergy; 2024 Mar; 79(3):724-734. PubMed ID: 38009241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
    Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
    Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
    Hide M; Ohsawa I; Nurse C; Yu M;
    J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.
    Wong JCY; Chiang V; Lam DLY; Lee E; Lam K; Au EYL; Li PH
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100166. PubMed ID: 38024849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
    Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
    Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
    [No Abstract]   [Full Text] [Related]  

  • 12. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
    Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19.
    Papi A; Stapleton RD; Shore PM; Bica MA; Chen Y; Larbig M; Welte T
    Lung; 2023 Apr; 201(2):159-170. PubMed ID: 37000214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
    McKenzie A; Roberts A; Malandkar S; Feuersenger H; Panousis C; Pawaskar D
    Clin Transl Sci; 2022 Mar; 15(3):626-637. PubMed ID: 34859955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
    Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
    J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
    Valerieva A; Longhurst HJ
    Front Allergy; 2022; 3():952233. PubMed ID: 36172291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
    Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
    Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.
    Aygören-Pürsün E; Soteres D; Moldovan D; Christensen J; Van Leerberghe A; Hao J; Schranz J; Jacobson KW; Martinez-Saguer I
    Int Arch Allergy Immunol; 2017; 173(2):114-119. PubMed ID: 28662509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.